Leyden Labs, a Leiden, the Netherlands-based provider of a mucosal protection platform, raised $70M in funding.
The round was led by ClavystBio and Polaris Partners with participation from Qiming Venture Partners and continued backing from existing investors including GV and Casdin Capital.
The company intends to use the funds to support further development of its pipeline aimed at providing protection against respiratory viruses, such as influenza and coronaviruses.
Led by CEO Koenraad Wiedhaup, Leyden Labs is leveraging its mucosal protection platform to develop a portfolio of candidates aimed at providing protection against influenza, coronaviruses, and other respiratory viruses through a new class of broadly protective nasal sprays.
In addition to this financing, the company announced the acquisition of CoV Biotechnology Pte. Ltd., a Singapore-based biotech company with assets developed by Linfa Wang, a professor of emerging infectious diseases at Duke-NUS Medical School.
FinSMEs
09/01/2025